[go: up one dir, main page]

MX2019002185A - Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos. - Google Patents

Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.

Info

Publication number
MX2019002185A
MX2019002185A MX2019002185A MX2019002185A MX2019002185A MX 2019002185 A MX2019002185 A MX 2019002185A MX 2019002185 A MX2019002185 A MX 2019002185A MX 2019002185 A MX2019002185 A MX 2019002185A MX 2019002185 A MX2019002185 A MX 2019002185A
Authority
MX
Mexico
Prior art keywords
compositions
inhibition
methods related
rank signaling
pikfyve inhibitors
Prior art date
Application number
MX2019002185A
Other languages
English (en)
Inventor
Lichenstein Henri
Gayle Sophia
M Rothberg Jonathan
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2019002185A publication Critical patent/MX2019002185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al uso de inhibidores de PlKfyve para inhibir la señalización de rangos RANKL/RANK, así como a composiciones y métodos relacionados.
MX2019002185A 2016-08-25 2017-08-17 Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos. MX2019002185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379330P 2016-08-25 2016-08-25
PCT/US2017/047264 WO2018039022A1 (en) 2016-08-25 2017-08-17 Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling

Publications (1)

Publication Number Publication Date
MX2019002185A true MX2019002185A (es) 2019-09-19

Family

ID=59982446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002185A MX2019002185A (es) 2016-08-25 2017-08-17 Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.

Country Status (12)

Country Link
US (1) US20190192527A1 (es)
EP (1) EP3503925A1 (es)
JP (1) JP2019528305A (es)
KR (1) KR20190068519A (es)
CN (1) CN109952113A (es)
AU (1) AU2017316475A1 (es)
BR (1) BR112019003604A2 (es)
CA (1) CA3034453A1 (es)
MX (1) MX2019002185A (es)
RU (1) RU2019108279A (es)
TW (1) TW201811335A (es)
WO (1) WO2018039022A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175906A1 (en) 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
US20230042913A1 (en) * 2017-06-05 2023-02-09 The Council Of The Queensland Institute Of Medical Research A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
EP4100016A1 (en) * 2020-02-07 2022-12-14 AI Therapeutics, Inc. Anti-viral compositions and methods of use
CN111494388B (zh) * 2020-05-12 2022-04-05 暨南大学 Ym201636及其药学上可接受的盐在制备抗肠道病毒感染药物中的应用
KR20230157338A (ko) * 2021-03-16 2023-11-16 에이아이 테라퓨틱스, 인코포레이티드 항바이러스 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058297A1 (en) 2003-05-29 2008-03-06 Synta Pharmaceuticals Corp. Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20150021228A1 (en) * 2012-02-02 2015-01-22 Visunex Medical Systems Co., Ltd. Eye imaging apparatus and systems
US20150112888A1 (en) * 2013-10-15 2015-04-23 Zvi Klepar Video review and ranking process using media files
BR112016017112A2 (pt) * 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
US9525201B2 (en) * 2014-10-27 2016-12-20 Nokia Technologies Oy Hinge that serves as a radiator
JP6705828B2 (ja) * 2014-11-07 2020-06-03 エイアイ・セラピューティクス・インコーポレーテッド 腎癌の処置に使用するためのアピリモド
US10729694B2 (en) * 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
WO2016126707A1 (en) * 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same

Also Published As

Publication number Publication date
TW201811335A (zh) 2018-04-01
AU2017316475A1 (en) 2019-03-07
KR20190068519A (ko) 2019-06-18
CA3034453A1 (en) 2018-03-01
US20190192527A1 (en) 2019-06-27
EP3503925A1 (en) 2019-07-03
CN109952113A (zh) 2019-06-28
JP2019528305A (ja) 2019-10-10
RU2019108279A (ru) 2020-09-25
BR112019003604A2 (pt) 2019-05-21
WO2018039022A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
JOP20220242A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
EA201691916A1 (ru) Биарильные ингибиторы киназы
PH12019502348A1 (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
MX2019002185A (es) Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.
IL273875A (en) Methods and compounds for inhibiting expression of LDHA
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
NZ742742A (en) Compositions and methods for inhibiting arginase activity
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX380250B (es) Compuestos farmacéuticos inhibidores de cinasa chk-1.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX386861B (es) Composiciones inhibidoras de nitrificación microencapsuladas.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
IL276312A (en) Use of Alkoxypyrazoles as nitrification inhibitors
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
MA39824A (fr) Composés azole amido-substitués
AU2015311730A8 (en) CaMKII inhibitors and uses thereof